Bristol Myers Squibb's IZA-Bren Shows Significant Survival Gains in TNBC, ESCC; China Grants Priority Review
BMY sits 29% above its 52-week low of $42.52.
Summary
Bristol Myers Squibb's drug Izalontamab Brengitecan (IZA-Bren) showed significant improvements in overall survival (OS) and progression-free survival (PFS) for patients with Triple-Negative Breast Cancer (TNBC) and Esophageal Squamous Cell Carcinoma (ESCC). China's NMPA also accepted the New Drug Application (NDA) for IZA-Bren in ESCC for priority review, accelerating its potential market entry there. This adds to a strong run of positive pipeline news for BMY, including recent successful Phase 3 trials for other key drugs. The drug also demonstrated a manageable safety profile.
At the time of this announcement, BMY was trading at $54.90 on NYSE in the Life Sciences sector, with a market capitalization of approximately $112.2B. The 52-week trading range was $42.52 to $62.89. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.